Welcome to our dedicated page for Promis Neuroscie SEC filings (Ticker: PMN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ProMIS Neurosciences Inc. (Nasdaq: PMN) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, proxy statements and other key documents. ProMIS is a clinical-stage biotechnology company focused on antibody and vaccine candidates targeting toxic misfolded protein oligomers in neurodegenerative and other misfolded protein diseases, and its filings offer detailed insight into corporate actions, governance and clinical program updates.
Through recent Form 8-K filings, ProMIS has reported material events such as the implementation of a one-for-twenty-five reverse stock split of its common shares, effective November 28, 2025, and subsequent notification from Nasdaq that the company regained compliance with the $1.00 minimum bid price requirement. Other 8-Ks describe the recommendation of an independent Data and Safety Monitoring Board to advance the PRECISE-AD Phase 1b trial of PMN310 to the final dose escalation cohort, the establishment of an at-the-market offering program, and the appointment and compensation of directors and executives.
The company’s definitive proxy statement on Schedule 14A outlines matters submitted to shareholders, including authorization of the share consolidation and procedures for a virtual special meeting. These materials provide information on share structure proposals, voting results and corporate governance practices. Additional filings reference press releases reporting quarterly financial results, which are incorporated by reference into Item 2.02 of Form 8-K.
On Stock Titan, ProMIS filings are updated in line with EDGAR and can be reviewed alongside AI-powered summaries that explain the significance of each document. Investors can quickly see how reverse stock split mechanics, Nasdaq listing compliance, at-the-market offerings, and clinical trial milestones are described in official filings. Over time, this page will also aggregate annual reports on Form 10-K, quarterly reports on Form 10-Q, and insider transaction reports on Form 4 as they are filed, helping users track both the scientific and capital markets dimensions of PMN’s development.
Insider purchase recorded by ProMIS Neurosciences (PMN). On
ProMIS Neurosciences Inc. is seeking shareholder approval at a virtual Special Meeting for a proposed share consolidation (reverse split). Holders of record as of September 26, 2025 may attend online via a unique link after registration; materials are available at www.proxyvote.com and www.sedarplus.ca. Approval of Proposal No. 1 requires 66 2/3% of votes cast, and the Board unanimously recommends a vote FOR. The statement warns the consolidation will reduce the number of outstanding shares and the stated capital attributed to Common Shares, and will retroactively increase per‑share net loss for prior periods. The proxy explains voting mechanics, broker voting rules, and basic U.S. and Canadian tax considerations for shareholders.
Jeremy M. Sclar 2012 Irrevocable Family Trust reported a series of warrant exercises and a warrant purchase in ProMIS Neurosciences (PMN). On 07/25/2025 the JS Trust exercised three tranches of purchase warrants, each for 697,674 common shares, for a total of 2,093,022 shares, at an agreed exercise price of $0.83518 per share instead of the original scheduled prices of $2.02 and $2.50. Following those exercises the Trust reported beneficial ownership totals rising in steps to 3,710,459 shares. On 07/29/2025 the Trust acquired a new warrant to purchase 3,139,533 common shares at $1.25 per share (the warrant was purchased at $0.1875 per underlying share and expires in five years).
Jeremy M. Sclar 2012 Irrevocable Family Trust filed an Initial Statement of Beneficial Ownership reporting direct ownership of 1,617,437 common shares of ProMIS Neurosciences, Inc. (PMN) and multiple warrants convertible into additional common shares. Reported derivative holdings include 26,217 warrants (exercise $7.50, exp. 04/11/2028), 664,894 warrants (exercise $1.75, exp. 02/24/2029), and three tranches of purchase warrants from a July 31, 2024 private placement totaling 2,093,022 underlying shares across Tranche A, B and C (exercise prices of $2.02 for A and B, $2.50 for C; various exercisability and expiry conditions). The Form 3 identifies the reporting person as a Director and the filing is made by one reporting person.
ProMIS Neurosciences Inc. updated the employment terms of its Chief Scientific Officer, Dr. Neil Cashman, through an Amended and Restated Employment Agreement effective September 26, 2025. Dr. Cashman will remain on the board and continue in his role as Chief Scientific Officer.
The amended agreement sets an annual base salary of $500,000 CAD and an annual discretionary bonus targeted at 35% of base salary. Dr. Cashman received an option to purchase 165,000 common shares at Fair Market Value on the grant date, vesting 25% after one year and the balance in equal monthly installments over thirty-six months.
He is entitled to 9 months of salary and continued benefits if terminated without cause, and to 9 months of salary, accelerated vesting of time-based equity awards, and continued benefits in connection with a change in control. The company states there are no family relationships or related-party transactions requiring disclosure.
Neil K. Warma, Chief Executive Officer and Director of ProMIS Neurosciences Inc. (PMN), reported a Section 16 transaction on Form 4 showing the acquisition of derivative securities on 09/22/2025. The filing records an award of 600,000 stock options with an exercise price of $0.45 that expire on 09/22/2035. Following the reported transaction, Mr. Warma beneficially owns 600,000 options directly. The options vest with 25% vesting on September 1, 2026 and the remainder vesting ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
Insider option grant reported for ProMIS Neurosciences (PMN). Max A. Milbury, listed as Principal Accounting Officer, was granted an option to purchase 60,000 common shares at an exercise price of $0.45 per share on 09/22/2025. The option has an expiration date of 09/22/2035. Vesting: 25% vests on 09/01/2026, with the remainder vesting ratably over the next 36 months. The filing was signed 09/24/2025 and is a single-person Form 4.
ProMIS Neurosciences (PMN) reported an insider option grant to Neil Cashman, who serves as a director and Chief Scientific Officer. The report shows an option to purchase 165,000 common shares with a $0.45 exercise price, granted with a transaction date of 09/22/2025. The option becomes exercisable on 09/22/2025 and expires on 09/22/2035. Vesting is specified: 25% vests on September 1, 2026 and the remainder vests ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact for Mr. Cashman on 09/24/2025. The filing reflects a non-derivative underlying position of 165,000 common shares after the reported transaction.
ProMIS Neurosciences reported an insider equity award: Chief Development Officer Johanne Kaplan was granted an option to buy 165,000 common shares at a $0.45 exercise price. The option was granted on 09/22/2025, becomes exercisable beginning 09/22/2025, and expires on 09/22/2035. Under the disclosed vesting schedule, 25% of the option vests on 09/01/2026 and the remaining portion vests ratably over the following 36 months. The Form 4 was signed on behalf of Ms. Kaplan on 09/24/2025 by an attorney-in-fact.
Larry Douglas Altstiel, Chief Medical Officer and director of ProMIS Neurosciences Inc. (PMN), was granted stock options on 09/22/2025. The Form 4 reports an award of 165,000 option rights to purchase common shares at an exercise price of $0.45 per share. The instrument is an option with an expiration tied to 09/22/2035. The reporting person beneficially owns 165,000 shares following the transaction and these holdings are listed as direct ownership. Per the filing, 25% of the option shares vest on September 1, 2026 and the remainder vests ratably over the following 36 months. The Form 4 was signed by an attorney-in-fact on 09/24/2025.
FAQ
What is the current stock price of Promis Neuroscie (PMN)?
What is the market cap of Promis Neuroscie (PMN)?
